JP2019501141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501141A5 JP2019501141A5 JP2018527804A JP2018527804A JP2019501141A5 JP 2019501141 A5 JP2019501141 A5 JP 2019501141A5 JP 2018527804 A JP2018527804 A JP 2018527804A JP 2018527804 A JP2018527804 A JP 2018527804A JP 2019501141 A5 JP2019501141 A5 JP 2019501141A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- peptide
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 12
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 8
- 229960003668 docetaxel Drugs 0.000 claims 8
- 229960004679 doxorubicin Drugs 0.000 claims 8
- 229940109262 curcumin Drugs 0.000 claims 6
- 235000012754 curcumin Nutrition 0.000 claims 6
- 239000004148 curcumin Substances 0.000 claims 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 230000025220 protein targeting to vacuole Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910021389 graphene Inorganic materials 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100032889 Sortilin Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000014187 peptide receptors Human genes 0.000 claims 2
- 108010011903 peptide receptors Proteins 0.000 claims 2
- 108010014657 sortilin Proteins 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- BTUDGPVTCYNYLK-UHFFFAOYSA-N 2,2-dimethylglutaric acid Chemical compound OC(=O)C(C)(C)CCC(O)=O BTUDGPVTCYNYLK-UHFFFAOYSA-N 0.000 claims 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 1
- 229960001573 cabazitaxel Drugs 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259178P | 2015-11-24 | 2015-11-24 | |
| US62/259,178 | 2015-11-24 | ||
| PCT/CA2016/051379 WO2017088058A1 (en) | 2015-11-24 | 2016-11-24 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135993A Division JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501141A JP2019501141A (ja) | 2019-01-17 |
| JP2019501141A5 true JP2019501141A5 (enExample) | 2019-12-26 |
| JP6810146B2 JP6810146B2 (ja) | 2021-01-06 |
Family
ID=58762819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527804A Active JP6810146B2 (ja) | 2015-11-24 | 2016-11-24 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| JP2020135993A Active JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135993A Active JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11034727B2 (enExample) |
| EP (2) | EP3380495B1 (enExample) |
| JP (2) | JP6810146B2 (enExample) |
| CN (2) | CN108473541B (enExample) |
| AU (2) | AU2016358324B2 (enExample) |
| CA (2) | CA3071494C (enExample) |
| DK (1) | DK3380495T3 (enExample) |
| ES (1) | ES2882634T3 (enExample) |
| PL (1) | PL3380495T3 (enExample) |
| PT (1) | PT3380495T (enExample) |
| SI (1) | SI3380495T1 (enExample) |
| WO (1) | WO2017088058A1 (enExample) |
| ZA (1) | ZA201804117B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6810146B2 (ja) * | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス．ウ．セ． | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| US11389460B2 (en) | 2017-09-15 | 2022-07-19 | City Of Hope | Methods and compositions for treating endometrial cancer |
| BR112020015202A2 (pt) * | 2018-03-01 | 2020-12-29 | Glycotope Gmbh | Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15 |
| AU2019324747A1 (en) * | 2018-08-24 | 2021-04-01 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
| WO2020254683A2 (en) * | 2019-06-20 | 2020-12-24 | Aarhus Universitet | Sorcs2 crystal structure and uses thereof |
| AU2020395148A1 (en) * | 2019-12-06 | 2022-06-23 | Theratechnologies Inc. | Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer |
| US20230338555A1 (en) * | 2020-05-18 | 2023-10-26 | Ionis Pharmaceuticals, Inc. | Conjugated oligonucleotides and uses thereof |
| US20240156971A1 (en) * | 2021-02-26 | 2024-05-16 | Transfert Plus, Société En Commandite | Methods and sortilin binding conjugate compounds for targeting cancer stem cells |
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| CN117904303B (zh) * | 2024-03-18 | 2024-06-18 | 湖南宏雅基因技术有限公司 | Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用 |
| CN118384289A (zh) * | 2024-04-24 | 2024-07-26 | 青岛科技大学 | 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| FI101678B1 (fi) | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US8344211B2 (en) | 2008-08-13 | 2013-01-01 | Ceres, Inc. | Plant nucleotide sequences and corresponding polypeptides |
| TW200634019A (en) | 2004-12-21 | 2006-10-01 | Wyeth Corp | Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors |
| EP2037948B1 (en) * | 2006-05-30 | 2016-04-13 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| EP2077278A1 (fr) * | 2007-12-21 | 2009-07-08 | Centre National de la Recherche Scientifique (CNRS) | Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques |
| CN102131826B (zh) * | 2008-04-27 | 2014-07-02 | H.隆德贝克有限公司 | 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途 |
| US20120039865A1 (en) * | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8147849B2 (en) | 2009-02-20 | 2012-04-03 | Novartis Ag | Protective antigens for group B Streptococcus hypervirulent strains |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| CA2786255A1 (en) | 2009-12-31 | 2011-07-07 | Organomed Corporation | Formulations from natural products, turmeric, and aspirin |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| LT3280441T (lt) * | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| JP6810146B2 (ja) * | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス．ウ．セ． | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| AU2019324747A1 (en) * | 2018-08-24 | 2021-04-01 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
-
2016
- 2016-11-24 JP JP2018527804A patent/JP6810146B2/ja active Active
- 2016-11-24 CA CA3071494A patent/CA3071494C/en active Active
- 2016-11-24 CN CN201680078822.9A patent/CN108473541B/zh active Active
- 2016-11-24 ES ES16867488T patent/ES2882634T3/es active Active
- 2016-11-24 EP EP16867488.5A patent/EP3380495B1/en active Active
- 2016-11-24 EP EP21174271.3A patent/EP3925969B1/en active Active
- 2016-11-24 US US15/778,626 patent/US11034727B2/en active Active
- 2016-11-24 WO PCT/CA2016/051379 patent/WO2017088058A1/en not_active Ceased
- 2016-11-24 CA CA3006313A patent/CA3006313C/en active Active
- 2016-11-24 SI SI201631303T patent/SI3380495T1/sl unknown
- 2016-11-24 PL PL16867488T patent/PL3380495T3/pl unknown
- 2016-11-24 CN CN202310436312.6A patent/CN116478245A/zh active Pending
- 2016-11-24 DK DK16867488.5T patent/DK3380495T3/da active
- 2016-11-24 AU AU2016358324A patent/AU2016358324B2/en active Active
- 2016-11-24 PT PT168674885T patent/PT3380495T/pt unknown
-
2018
- 2018-06-20 ZA ZA2018/04117A patent/ZA201804117B/en unknown
-
2020
- 2020-08-11 JP JP2020135993A patent/JP7095035B2/ja active Active
-
2021
- 2021-02-19 AU AU2021201085A patent/AU2021201085B2/en active Active
- 2021-04-23 US US17/239,544 patent/US11780882B2/en active Active
-
2023
- 2023-08-30 US US18/240,295 patent/US12269902B2/en active Active
-
2025
- 2025-03-11 US US19/076,662 patent/US20250296957A1/en active Pending